Q2 ‘03 Conference Call March 5, 2003

Forward-Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of These statements are based on current Company expectations and are subject to risks and uncertainties which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company’s success in enforcing its patents and protecting its proprietary products and manufacturing techniques and in integrating the operations of FSG into the Company’s existing business; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company’s global markets. Additional information regarding these and other factors is available on the Web at and is included in the Company’s reports filed with U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at:

Comparative Sales, Earnings & EPS

Q2 ‘03 Pro Forma to As Reported Numbers

Comparative Income Statements

Balance Sheet: Working Capital$ 515 M Stockholder’s Equity$ 844 M DSO 87 Inventory Turns 2.9 % of Net Debt/Net Debt + Equity 39 % Cash Flow: EBITDA$ 117 M Capex$ 28 M Dividends Paid$ 22 M Net Debt Reduction$ 41 M Balance Sheet & Cash Flow Data

Foreign Exchange Impact

Sales & Operating Profit – by Geography

Sales & Operating Profit – by Business $160.8 M $227.7 M $34.2 M $28.7 M

Life Sciences Sales & Operating Profit

Industrial Sales & Operating Profit

Outlook for FY ’03

FISCAL 2003 RANGE Original Expectation: $0.95 to $1.15 Mid-Year Outlook: $1.02 to $1.12 Earnings Outlook for 2003 Q3’03 RANGE 28 to 33 cents per share